Adults 2 to 17, any sex, with Juvenile Idiopathic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40)Primary· Week 16 through Week 40
JIA ACR30 flare is defined as a ≥ 30% worsening of 3 of 6 variables and no more than 1 of the remaining variables improving \> 30%. The 6 variables are physician global assessment of disease activity (worsening of 20 units minimum on a 0-100 visual analog scale \[VAS\]), parent/patient global assessment of overall well-being (worsening of 20 VAS units minimum), number of joints (minimum of 2 worse) with active arthritis (swelling, or pain and limitation of motion), number of joints (minimum of 2 worse) with limitation of movement, erythrocyte sedimentation rate, and functional ability assessed
Group
Value
95% CI
Placebo
48.1
37.0 – 59.0
Tocilizumab 8 or 10 mg/kg
25.6
16.0 – 35.0
Percent of Patients Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30, 50, 70, and 90 (ACR30/50/70/90) Responses in Part I of the Study (Baseline to Week 16)Secondary· Baseline to Week 16
A JIA ACR30/50/70/90 response is defined as a ≥ 30/50/70/90% response on 3 of 6 variables and no more than 1 of the remaining variables worsening \> 30%. The 6 variables are physician global assessment of disease activity (20 units minimum on a 0-100 visual analog scale \[VAS\]), parent/patient global assessment of overall well-being (20 VAS units minimum), number of joints (minimum of 2 worse) with active arthritis (swelling, or pain and limitation of motion), number of joints (minimum of 2 worse) with limitation of movement, erythrocyte sedimentation rate, and functional ability assessed usi
ACR30 response
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
88.6
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
76.5
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
93.3
Tocilizumab 8 or 10 mg/kg
89.4
ACR50 response
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
80.0
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
70.6
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
87.4
Tocilizumab 8 or 10 mg/kg
83.0
ACR70 response
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
62.9
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
41.2
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
68.1
Tocilizumab 8 or 10 mg/kg
62.2
ACR90 response
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
31.4
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
23.5
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
25.2
Tocilizumab 8 or 10 mg/kg
26.1
Percent Change From Baseline in the Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Component Score Physician Global Assessment of Disease Activity at the End of Part I of the Study (Week 16)Secondary· Baseline to Week 16
The patient's treating physician provides a rating of the patient's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end represents 'arthritis very active'. A higher score indicates more disease activity. A negative change score indicates improvement.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
-61.48
± 48.779
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
-65.20
± 26.170
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
-72.61
± 25.977
Tocilizumab 8 or 10 mg/kg
-69.19
± 31.824
Percent Change From Baseline in the Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Component Score Patient/Parent Global Assessment of Overall Well-being at the End of Part I of the Study (Week 16)Secondary· Baseline to Week 16
The patient or parent/guardian, as appropriate, provides a rating of the patient's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end represents 'very poor' (ie, maximum arthritis disease activity). A higher score indicates poorer well-being. A negative change score indicates improvement.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
-31.65
± 120.268
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
-55.56
± 42.092
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
-53.34
± 58.686
Tocilizumab 8 or 10 mg/kg
-49.46
± 72.920
Percent Change From Baseline in the Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Component Score Number of Joints With Active Arthritis at the End of Part I of the Study (Week 16)Secondary· Baseline to Week 16
Joints with active arthritis are defined as joints with swelling present or pain present and limitation of motion. The maximum number of joints with active arthritis is 71. The joint assessment is performed by an independent assessor who is not the treating physician and who is blinded to all other aspects of the patient's efficacy and safety data. A negative change score indicates improvement.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
-63.36
± 43.272
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
-55.57
± 44.876
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
-72.96
± 33.915
Tocilizumab 8 or 10 mg/kg
-68.15
± 38.246
Percent Change From Baseline in the Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Component Score Number of Joints With Limitation of Movement at the End of Part I of the Study (Week 16)Secondary· Baseline to Week 16
Joints with limitation of movement are defined as joints with limitation of motion. The maximum number of joints with limitation of movement is 67. The joint assessment is performed by an independent assessor who is not the treating physician and who is blinded to all other aspects of the patient's efficacy and safety data. A negative change score indicates improvement.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
-61.83
± 34.726
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
-49.87
± 48.091
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
-65.96
± 30.134
Tocilizumab 8 or 10 mg/kg
-62.42
± 34.955
Percent Change From Baseline in the Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Component Score Erythrocyte Sedimentation Rate (ESR) at the End of Part I of the Study (Week 16)Secondary· Baseline to Week 16
Erythrocyte sedimentation rate, an acute phase protein, was measured using a kit furnished by the study central laboratory. A negative change score indicates improvement.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
-70.98
± 24.530
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
-21.84
± 159.592
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
-70.87
± 33.400
Tocilizumab 8 or 10 mg/kg
-62.54
± 73.384
Percent Change From Baseline in the Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Component Score Functional Ability at the End of Part I of the Study (Week 16)Secondary· Baseline to Week 16
Functional ability is assessed with the Childhood Health Assessment Questionnaire (CHAQ-DI) disability index which consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. If aids and devices listed in the questionnaire or assistance from a person are required to perform a task, a domain score of 0 or 1 is increased to 2; if the domain score
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
-54.48
± 37.214
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
-46.16
± 50.961
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
-49.07
± 45.048
Tocilizumab 8 or 10 mg/kg
-49.62
± 44.573
Juvenile Arthritis Disease Activity Score (JADAS-27) at the End of Part I of the Study (Week 16)Secondary· Week 16
The JADAS-27 is derived from the following components: Physician's global assessment of disease activity on a 0-100 mm visual analog scale (VAS)/10, patient/parent's global assessment of overall well-being on a 0-100 mm VAS/10, normalized erythrocyte sedimentation rate (ESR) (if ESR is ≤ 20 then set to 0, if ≥ 120 then set to 10, and if \> 20 and \< 120 then apply formula \[ESR-20\]/10), and number of joints (maximum of 27) with active arthritis (cervical spine, left/right elbow, left/right wrist, left/right MCP1-3, left/right PIP1-5, left/right hips, left/right knee and left/right ankle). The
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
9.08
± 8.882
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
12.25
± 10.277
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
7.83
± 7.122
Tocilizumab 8 or 10 mg/kg
8.82
± 8.198
Pain Visual Analogue Scale (VAS) Score at the End of Part I of the Study (Week 16)Secondary· Week 16
The patient or parent/guardian, as appropriate, provides a rating of the patient's pain (also called a discomfort index) on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'no pain' and the extreme right end represents 'very extreme pain'. A higher score indicates more pain.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
21.9
± 21.66
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
24.1
± 23.94
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
20.3
± 21.13
Tocilizumab 8 or 10 mg/kg
21.2
± 21.65
Percent of Patients With Inactive Disease at the End of Part I of the Study (Week 16)Secondary· Week 16
A patient is judged to have inactive disease if all of the following criteria are met: Number of joints with active arthritis = 0; absence of active uveitis, defined by the adverse event preferred terms 'uveitis' and 'intermediate uveitis'; normal erythrocyte sedimentation rate (\< 20 mm/hour regardless of age and sex); and physician's global assessment of overall well-being visual analog scale score ≤ 10.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
20.0
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
8.8
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
18.5
Tocilizumab 8 or 10 mg/kg
17.0
Percent of Patients With an Elevated C-reactive Protein Concentration at Baseline That Had Normalized at the End of Part I of the Study (Week 16)Secondary· Baseline to Week 16
C-reactive protein (CRP), an acute phase protein, was measured in blood samples with a high-sensitivity CRP (hs-CRP) test using laser nephelometry.
Group
Value
95% CI
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
76.9
Tocilizumab 8 mg/kg in Patients Weighing < 30 kg
63.2
Tocilizumab 8 mg/kg in Patients Weighing ≥ 30 kg
87.0
Tocilizumab 8 or 10 mg/kg
79.5
Adverse events — posted to ClinicalTrials.gov
Time frame: All exposure safety population: All participants randomized into Part I of the study who received at least 1 infusion of tocilizumab and had at least 1 post-baseline safety assessment or event..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Tocilizumab 10 mg/kg in Patients Weighing < 30 kg
Serious: 4/22 (18%)
Deaths: —
Tocilizumab 10 mg/kg to 8 mg/kg in Patients Weighing < 30 kg
This 3-part study evaluated the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis who have an inadequate response to, or were intolerant of methotrexate. In Part I of the study, all patients received intravenous (iv) infusions of tocilizumab (8 mg/kg for patients ≥ 30kg, 8 mg/kg or 10 mg/kg for patients \< 30kg) every 4 weeks for 16 weeks. In Part II of the study, patients with an adequate response in Part I were randomized to receive either tocilizumab at the same dose as in Part I or placebo every 4 weeks for up to 24 weeks. In Part III of the study, patients received tocilizumab at the same dose as in Part I every 4 weeks for up to another 64 weeks. Standard of care therapy with or without non-steroidal anti-inflammatory drugs (NSAID), corticosteroids, or methotrexate was continued throughout the study.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder
· Phase 2
· suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu
· Phase 3
· recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
· not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra
· Phase 2
· not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post
· Phase 3
· recruiting
Other recruiting trials for Juvenile Idiopathic Arthritis
Currently open trials in the same condition.
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose
· recruiting
NCT05879419 — Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
· Phase 4
· active not recruiting
NCT06007456 — Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
· recruiting
NCT03913962 — Health and Exercise Response in Children With Chronic and Auto-immune Pathologies
· NA
· recruiting
NCT06560606 — UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
· recruiting
Other Hoffmann-La Roche trials
Trials by the same sponsor.
NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O
· Phase 2
· not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in
· Phase 3
· recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations
· not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
· Phase 3
· recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric
· Phase 3
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 26 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00988221.